Corporate Profile

Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company has completed enrollment in a Phase 2 trial to advance its novel echinocandin antifungal, rezafungin acetate, formerly called CD101 IV, and is developing bispecific antibiotic immunotherapies for the treatment of multi-drug resistant Gram-negative bacterial infections. Rezafungin has improved pharmacokinetics compared to existing echinocandins and has the potential for expanded utility across patient settings. Rezafungin is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara has received a grant for up to $6.9 million from CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) to advance the development of CD201 and back-up molecules. Cidara is headquartered in San Diego, California.

Stock Information

CDTX (Common Stock)
PriceChange% ChangeVolume
$7.60 - 0.050.65%3,205
Previous CloseToday's OpenIntraday HighIntraday Low
$7.65$7.60$7.65$7.60
Exchange: NASDAQ (US Dollar)
12/11/17 9:54 a.m. ET
Refresh quote

 

Stock chart for: CDTX.O.  Currently trading at $7.60 with a 52 week high of $11.75 and a 52 week low of $5.60.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources